India, March 11 -- Merck, known as MSD outside of the United States and Canada, has announced the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina site in the US.

This expansion of the Durham plant is a crucial component of the more than $12 billion Merck has invested toward US capital investment since 2018 focused on expanding domestic manufacturing and research and development capabilities and creating new jobs in the US, with another $8 billion of US capital investment expected by 2028.

"Expanding our state-of-the-art manufacturing facility in Durham marks a significant milestone in our efforts to strengthen our production and manufacturing capabilities in the...